Abstract Library

#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3

Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Friend E, Gray D, Fernández Ortega P, McNamara M, Kaltsas G,

Keywords: research, neuroendocrine, insulinoma, gastrinoma, non-functioning, VIPoma, Glucagonoma, questionnaire, quality of life,

#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mansfield A

Authors: Mansfield A, Aggarwal R, Beltran H, Farago A, Hann C,

Keywords: Rovalpituzumab tesirine, DLL3, neuroendocrine tumors, antibody-drug conjugate,

#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers

Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Antonijoan Arbós R, Lachamp L, Cabello F, Molina P, Coimbra J,

Keywords: Apoc, somatostatin, analogues, controlled release, octreotide, octreotide acetate, phase 1, studies, clinical trial, study, neuroendocrine, tumor, slow, release, formulation, therapeutics, injection, drug effect, clinical, trial, im, sc,

#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: Radiolabelled somatostatin antagonist, PET, GEP-NET,

#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Tamagno G

Authors: Tamagno G, Crespo G, Fierro Maya F, Fossmark R, Igaz P,

Keywords: neuroendocrine tumor, clinical trial, hallmark,